1. Articles from Cheung IY , et al.

    1-1 of 1
    1. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Oncoimmunology. 2017;6(11):e1358331

      Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

      Read Full Article
      Mentions: Antibody
    1-1 of 1
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (1 articles) Antibody
  3. Popular Articles

  4. Picture Gallery

    Childhood cancer survivors may develop heart problems sooner New biomarkers for neuroblastoma, a type of cancer in children Autolus’ solid tumour CAR-Ts will have ‘off switch’ Antibody-Drug Conjugate Field Expanding in Oncology Epigenetic analysis: Giving the right name to a tumor CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways Study identifies two new biomarkers for common form of childhood cancer A molecular map of childhood cancers Long Noncoding RNA pancEts-1 Promotes Neuroblastoma Progression through hnRNPK-Mediated {beta}-Catenin Stabilization Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions